Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced a marketing collaboration with Movendo Technology to enhance its Real Intelligence ecosystem with personalized robotic rehabilitation capabilities. This collaboration, initiated in Europe, focuses on Movendo's HUNOVA rehabilitation device, which analyzes biomechanics to create individualized recovery programs. This partnership aims to improve patient outcomes through integrated robotics-assisted surgery and rehabilitation. The CORI Surgical System will also launch in Europe after its successful introduction in the U.S. in 2020.
Smith+Nephew (NYSE:SNN) announced a real-world study from Spain showing that their ALLEVYN LIFE Foam Dressings significantly reduced dressing change frequency by 47.1% and weekly dressing costs by 58.7%. Conducted across 24 primary care centers and six nursing homes, the study included 94 patients with a median age of over 70. Healthcare professionals noted improved patient satisfaction and treatment experiences despite fewer nursing visits, showcasing ALLEVYN LIFE's effective exudate management and cost efficiency in wound care.
Smith+Nephew (LSE:SN, NYSE:SNN) announced a new publication highlighting that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) reduces surgical site infections (SSIs) by 63%, seroma by 77%, and dehiscence by 30%. The systematic review covered 29 studies with 5,614 patients, demonstrating the therapy's efficiency across various surgical specialties. The PICO sNPWT also decreases hospital stay length by nearly 2 days, potentially benefiting healthcare systems significantly. This evidence supports PICO therapy for preventing surgical complications effectively.
Smith+Nephew (NYSE: SNN) has successfully launched a new inventory automation solution in partnership with Movemedical in the US. This platform aims to simplify field sales operations for better inventory management, ensuring timely product delivery to customers. The solution enhances logistics and real-time data access, empowering sales teams to meet customer needs effectively. Smith+Nephew integrated this system across its entire US Orthopaedic sales force in just over a week, highlighting its operational efficiency.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced exceptional clinical outcomes for its total hip arthroplasty (THA) portfolio, achieving the highest implant survivorship of 98.46% at ten years in the National Joint Registry for England, Wales, and Northern Ireland. Their POLAR3 Total Hip Solution also boasts a 72% lower revision risk compared to the class average. Additionally, the Australian Orthopaedic Association Registry reported a 94.5% survivorship at 15 years with the proprietary OXINIUM Technology, which reduces revision risk by 39-41% compared to traditional options.
Smith+Nephew (NYSE:SNN) has launched RI.INSIGHTS, a pioneering platform aimed at enhancing robotics-assisted surgeries. This tool allows orthopedic surgeons to benchmark their surgical experiences against peers and utilize intra and post-operative data to improve patient outcomes. The platform, part of the Real Intelligence portfolio, aims to drive advancements in digital health and robotics surgery. Currently available on a limited basis, a full commercial release is planned for 2021. Smith+Nephew generated $5.1 billion in sales in 2019, emphasizing its commitment to innovation in orthopedic technology.
Smith+Nephew (NYSE:SNN) announced positive two-year follow-up results from the STITCH Study for its NOVOSTITCH Meniscal Repair Systems. This first-of-its-kind trial demonstrated an impressive clinical success rate of 82.6%, with significant improvements in all Patient Reported Outcome Measures (PROMs) at p<0.001. Complete meniscal healing was observed in 100% of patients evaluated at six months. The study emphasizes a shift towards meniscal repair, which could prevent long-term complications like osteoarthritis associated with meniscectomy. The NOVOSTITCH system offers innovative solutions for complex meniscal tears.
Smith+Nephew (NYSE:SNN) has enhanced its ARIA digital care management platform with new tools: ARIA SiteSelect and ARIA Optimized Recovery Pathways. These innovations aim to assist clinicians in accurately determining suitable outpatient surgery candidates and standardizing total joint care pathways for improved post-operative outcomes. Utilizing patient history and lifestyle data, ARIA SiteSelect helps identify optimal surgical sites, while the 90-day recovery pathways are designed to reduce complications and enhance patient mobility post-surgery.
Smith+Nephew (NYSE: SNN) has announced the upcoming launch of ARIA Home PT, a remote physical therapy module for its ARIA digital care management platform, set for early 2021. This module includes a virtual coaching system utilizing 3D motion capture technology, aiming to enhance patient recovery and expand access to post-acute care. Telehealth functionalities will follow soon after. The initiative is part of Smith+Nephew's investment in its Positive Connections program, addressing the growing demand for digital health solutions.
Smith+Nephew (NYSE:SNN) has been awarded Most Innovative at the 2020 Gartner Communications Awards for its T.I.M.E. clinical decision support tool (CDST), which addresses the lack of consistent wound assessment practices among specialists. Developed through collaboration with international experts, the tool aims to improve clinical outcomes by standardizing care delivery. The campaign has seen significant customer engagement, generating multiple publications and a consensus document by the World Union of Wound Healing Societies. This recognition highlights Smith+Nephew’s commitment to enhancing patient care and stakeholder engagement.